Climacteric medicine where do we go?
At a time when ongoing research and clinical investigation into the use of HRT in perimenopausal women are incomplete--and when certain controversies remain unresolved--this summary of current opinion and knowledge fills the need for authoritative reference on this topic. Written by a 'Blue Rib...
Saved in:
Corporate Authors: | , |
---|---|
Other Authors: | , |
Format: | Book |
Language: | English |
Published: |
London New York
Taylor & Francis
2005
|
Subjects: | |
Online Access: | Click Here to View Status and Holdings. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
MARC
LEADER | 00000nam a2200000#i 4501 | ||
---|---|---|---|
001 | wils-338757 | ||
005 | 202336151252 | ||
008 | 230406t2005 -UK a# #001 deng D | ||
020 | # | # | |a 9781842142615 |q hardback |
020 | # | # | |a 1842142615 |q hardback |
040 | # | # | |a DNLM |c DNLM |d UiTM |e rda |
041 | 0 | # | |a english |
060 | 0 | 0 | |a WP 580 |
090 | 0 | 0 | |a WP580 |b I34c 2005 |
111 | 1 | # | |a IMS Workshop |c Vienna, Austria) |d 2003 : |n (4th : |
245 | 0 | 0 | |a Climacteric medicine |b where do we go? |c edited by Hermann P. G. Schneider and Frederick Naftolin |
264 | # | 1 | |a London |a New York |b Taylor & Francis |c 2005 |
264 | # | 4 | |c ©2005 |
300 | # | # | |a xiii, 236 pages |b illustrations |c 21 cm |
336 | # | # | |a text |b txt |2 rdacontent |
337 | # | # | |a unmediated |b n |2 rdamedia |
338 | # | # | |a volume |b nc |2 rdacarrier |
500 | # | # | |a "Published under the auspices of the International Menopause Society." |
504 | # | # | |a Includes bibliographical references and index |
520 | # | # | |a At a time when ongoing research and clinical investigation into the use of HRT in perimenopausal women are incomplete--and when certain controversies remain unresolved--this summary of current opinion and knowledge fills the need for authoritative reference on this topic. Written by a 'Blue Ribbon' panel, the book addresses the wide range of advances in clinical practice for the climacteric in diagnostic technology and to therapeutic choices. In order to provide optimal assistance in determining an individual women's risk-profile --and properly to assess the potential of therapeutic intervention--the biological and practical rationale of all existing HRT agents are reviewed. Key feature *Addresses the wide range of advances in clinical practice for the climacteric *Provides current opinion and information on the use of HRT in perimenopausal women *Reviews the biological and practical rationale of all existing HRT agents |
650 | 1 | 2 | |a Hormone Replacement Therapy |v Congress |x adverse effects |
650 | 1 | 2 | |a Menopause |v Congress |
650 | 2 | 2 | |a Estrogens |v Congress |x adverse effects |
650 | 2 | 2 | |a Estrogens |v Congress |x therapeutic use |
650 | 2 | 2 | |a Progestins |v Congress |x adverse effects |
650 | 2 | 2 | |a Progestins |v Congress |x therapeutic use |
650 | 2 | 2 | |a Risk Assessment |v Congress |
700 | 1 | # | |a Schneider, H. P. G. |e editor |q Hermann P. G. |
700 | 1 | # | |a Naftolin, Frederick |e editor |
710 | 2 | # | |a International Menopause Society |
856 | 4 | 0 | |z Click Here to View Status and Holdings. |u https://opac.uitm.edu.my/opac/detailsPage/detailsHome.jsp?tid=338757 |
964 | # | # | |c BOK |d 01 |
998 | # | # | |a 00264#1a006.2.2||00264#1a002.8.2||00264#1b006.2.2||00300##a006.2.2||00300##b006.2.2||00300##c006.2.2||00500##a006.2.2||00520##a006.2.2||00520##b006.2.2|| |